



## **DOAC-Stop #X9904**

### Product description:

DOAC-Stop efficiently removes all types of DOACs including dabigatran, apixaban, rivaroxaban and edoxaban, from test plasmas with minimal effect on currently-known clotting variables.

### Background:

Direct Oral Anti-Coagulants (DOACs) are increasing in therapeutic uses and are known to interfere with almost all clotting tests to varying degrees. Thus plasmas giving unexpectedly prolonged clotting time or abnormal chromogenic test results may need to be screened for the presence of DOACs if this is clinically relevant.

Reversing agents for individual DOACs are being developed for therapeutic use but are not yet widely available for lab tests. DOAC-Stop is the first general agent available for simplifying the diagnostic problems associated with DOACs.

### Significance:

The degree of shortening induced by DOAC- Stop in a clotting time test can be used as a guide to the presence and concentration of DOACs. (Please ask for more information if needed. A uniformly DOAC-sensitive test such as "DOAC-Test", a RVV-based Haematex reagent may be best; Sennesael AL, et al, Thromb. Res. 2017; 157; 29-37).

Clotting tests on patient plasmas treated with DOAC-Stop can be used for more reliable routine assessment of known blood coagulation parameters (Exner et al, submitted, 2017). Thus, more rapid testing for underlying plasma defects, possibly contributing to a bleeding or clotting episode can be carried out.

### Presentation:

Plastic vials containing specified numbers of mini tablets (tabs). Each 18mg tablet contains enough DOAC-Stop agent for processing 1ml of citrated test plasma (0.5-1.5ml is acceptable). Products are stable at ambient temperature for over 5 years if kept dry.

### Method for DOAC removal from a test plasma:

1. Add the volume of citrated test plasma to be treated (0.5-1.5ml) to a plastic centrifuge tube containing 1 DOAC Stop mini-tab (or powder) and mix gently for 5 minutes.
2. Centrifuge down the particulate matter. (eg. 2 minutes at 2000g).
3. The supernatant plasma, now depleted of DOACs can be used directly for testing.  
Or transfer it to another separate tube for frozen storage.

**NOTE:** Only for research use or evaluation. This product has not yet been fully tested on all possible patient conditions. Further information available on request.  
(AUS Patent application date 15.02.2017).

TE.v.161117